explore -WSS

explore

author：entertainment 2025-10-01 02:28:09 - browse：24869

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

explore

WSS

Ripples from Flovent's discontinuation is killing children with asthma

Supreme Court to hear if Covid misinformation is protected speech

Ripples from Flovent's discontinuation is killing children with asthma

Fertility clinic egg and embryo storage is a disaster

Free medical tuition alone isn't enough to close gaps in primary care

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

knowledge

explore

Bluebird and the case for gene therapy profits

explore

Moonlake's readout produced a cash windfall. Risks remain

Cherokee Nation medical school graduates its first class

Guidelines to prevent youth baseball injuries need more muscle

Where does female orgasm come from? Scientists think they know

In age of alternative facts, a scholarly course on calling out crap

WuXi Biologics beefs up its lobbying operation

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Free medical tuition alone isn't enough to close gaps in primary care

23andMe had bad news about my health. I wish a person had delivered it

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

focus

Fertility clinic egg and embryo storage is a disaster

The response to Covid

WuXi Biologics beefs up its lobbying operation

STAT series 'Denied by AI' wins major journalism prizes

Severe heat forecast: Where scorching temperatures will persist over the next week

Severe heat forecast: Where scorching temperatures will persist over the next week

Wikipedia

explore

hotspot

entertainment